| Outcome |
Relative effect 95%CI |
LoD |
Trt. better when |
|
I2 |
k (RCT/OBS)
|
Bayesian probability
|
Overall ROB
|
Publication bias |
Degree of certainty |
Endpoint importance |
Published MA |
efficacy endpoints 00 |
| deaths (OS) | 0.60 [0.51, 0.72] | | < 1 | | 0% | 3 studies (3/-) | 100.0 % | low | not evaluable | high | crucial | - |
| deaths (OS) (extension) | 0.58 [0.48, 0.69] | | < 1 | | 43% | 2 studies (2/-) | 100.0 % | low | not evaluable | high | important | - |
| PFS (extension) | 0.45 [0.37, 0.56] | | < 1 | | 52% | 3 studies (3/-) | 100.0 % | low | not evaluable | high | important | - |
| progression or deaths (PFS) | 0.47 [0.37, 0.60] | | < 1 | | 32% | 3 studies (3/-) | 100.0 % | low | not evaluable | high | important | - |
| objective responses (ORR) | 6.69 [2.96, 15.13] | | > 1 | | 84% | 3 studies (3/-) | 100.0 % | low | not evaluable | high | non important | - |
| objective responses (ORR) (extension) | 5.68 [3.20, 10.11] | | > 1 | | 75% | 3 studies (3/-) | 100.0 % | low | not evaluable | high | non important | - |
safety endpoints 00 |
| TRAE (any grade) | 1.51 [0.55, 4.16] | | < 1 | | 83% | 3 studies (3/-) | 21.2 % | low | not evaluable | high | non important | - |
| TRAE (grade 3-4) | 2.14 [0.61, 7.44] | | < 1 | | 96% | 3 studies (3/-) | 11.7 % | low | not evaluable | high | non important | - |
| TRAE leading to death (grade 5) | 0.99 [0.06, 15.92] | | < 1 | | 0% | 2 studies (2/-) | 50.2 % | low | not evaluable | high | non important | - |
| TRAE leading to discontinuation (any grade) | 2.24 [0.64, 7.85] | | < 1 | | 94% | 3 studies (3/-) | 10.3 % | low | not evaluable | high | non important | - |
| TRAE leading to discontinuation (grade 3-4) | 1.74 [0.50, 6.11] | | < 1 | | 93% | 3 studies (3/-) | 19.3 % | low | not evaluable | high | non important | - |
TRAE (grade 3-4) endpoints 00 |
| Abdominal pain TRAE (grade 3-4) | 0.34 [0.06, 1.80] | | < 1 | | 0% | 3 studies (3/-) | 89.6 % | low | not evaluable | high | non important | - |
| Adrenal insufficiency TRAE (grade 3-4) | 1.52 [0.23, 9.87] | | < 1 | | 49% | 3 studies (3/-) | 33.2 % | low | not evaluable | high | non important | - |
| Arthralgia TRAE (grade 3-4) | 1.85 [0.26, 13.41] | | < 1 | | 0% | 3 studies (3/-) | 27.2 % | low | not evaluable | high | non important | - |
| Asthenia TRAE (grade 3-4) | 0.49 [0.10, 2.35] | | < 1 | | 0% | 3 studies (3/-) | 81.1 % | low | not evaluable | high | non important | - |
| Chills TRAE (grade 3-4) | 0.49 [0.01, 24.92] | | < 1 | | 0% | 1 study (1/-) | 63.7 % | NA | not evaluable | | non important | - |
| Colitis TRAE (grade 3-4) | 0.73 [0.15, 3.51] | | < 1 | | 86% | 3 studies (3/-) | 65.5 % | low | not evaluable | high | non important | - |
| Constipation TRAE (grade 3-4) | 0.98 [0.03, 29.71] | | < 1 | | 0% | 1 study (1/-) | 50.5 % | NA | not evaluable | | non important | - |
| Cough TRAE (grade 3-4) | 2.34 [0.21, 26.66] | | < 1 | | 0% | 2 studies (2/-) | 24.9 % | low | not evaluable | high | non important | - |
| Decreased appetite TRAE (grade 3-4) | 1.66 [0.31, 8.80] | | < 1 | | 0% | 3 studies (3/-) | 27.8 % | low | not evaluable | high | non important | - |
| Diarrhoea TRAE (grade 3-4) | 0.95 [0.42, 2.14] | | < 1 | | 65% | 3 studies (3/-) | 54.9 % | low | not evaluable | high | non important | - |
| Dry skin TRAE (grade 3-4) | 1.36 [0.62, 2.95] | | < 1 | | 0% | 2 studies (2/-) | 22.2 % | low | not evaluable | high | non important | - |
| Dyspnoea TRAE (grade 3-4) | 3.44 [0.57, 20.83] | | < 1 | | 0% | 3 studies (3/-) | 9.1 % | low | not evaluable | high | non important | - |
| Endocrine disorders TRAE (grade 3-4) | 1.24 [0.23, 6.63] | | < 1 | | 0% | 1 study (1/-) | 40.3 % | NA | not evaluable | | non important | - |
| Fatigue TRAE (grade 3-4) | 2.66 [0.95, 7.46] | | < 1 | | 12% | 3 studies (3/-) | 3.2 % | low | not evaluable | high | non important | - |
| Gastrointestinal disorders TRAE (grade 3-4) | 2.22 [0.77, 6.34] | | < 1 | | 0% | 1 study (1/-) | 6.9 % | NA | not evaluable | | non important | - |
| Headache TRAE (grade 3-4) | 1.43 [0.27, 7.51] | | < 1 | | 0% | 3 studies (3/-) | 33.8 % | low | not evaluable | high | non important | - |
| Hepatitis TRAE (grade 3-4) | 3.83 [0.60, 24.27] | | < 1 | | 0% | 3 studies (3/-) | 7.8 % | low | not evaluable | high | non important | - |
| Hepatobiliary disorders TRAE (grade 3-4) | 15.93 [0.93, 273.74] | | < 1 | | 0% | 1 study (1/-) | 3.0 % | NA | not evaluable | | non important | - |
| Hyperthyroidism TRAE (grade 3-4) | 1.88 [0.25, 14.47] | | < 1 | | 0% | 3 studies (3/-) | 27.2 % | low | not evaluable | high | non important | - |
| Hypophysitis TRAE (grade 3-4) | 0.61 [0.24, 1.59] | | < 1 | | 0% | 3 studies (3/-) | 84.3 % | low | not evaluable | high | non important | - |
| Hypothyroidism TRAE (grade 3-4) | 1.06 [0.12, 9.11] | | < 1 | | 0% | 3 studies (3/-) | 47.9 % | low | not evaluable | high | non important | - |
| Increase AST TRAE (grade 3-4) | 4.79 [1.35, 17.01] | | < 1 | | 25% | 3 studies (3/-) | 0.8 % | low | not evaluable | high | non important | - |
| Increased ALT TRAE (grade 3-4) | 3.07 [0.64, 14.80] | | < 1 | | 69% | 3 studies (3/-) | 8.1 % | low | not evaluable | high | non important | - |
| Increased lipase level TRAE (grade 3-4) | 2.11 [0.98, 4.53] | | < 1 | | 46% | 3 studies (3/-) | 2.8 % | low | not evaluable | high | non important | - |
| Maculopapular rash TRAE (grade 3-4) | 3.55 [0.87, 14.52] | | < 1 | | 0% | 3 studies (3/-) | 3.9 % | low | not evaluable | high | non important | - |
| Myalgia TRAE (grade 3-4) | 1.36 [0.17, 10.56] | | < 1 | | 0% | 3 studies (3/-) | 38.6 % | low | not evaluable | high | non important | - |
| Nausea TRAE (grade 3-4) | 1.15 [0.21, 6.28] | | < 1 | | 35% | 3 studies (3/-) | 43.7 % | low | not evaluable | high | non important | - |
| Pneumonitis TRAE (grade 3-4) | 1.53 [0.37, 6.33] | | < 1 | | 0% | 3 studies (3/-) | 28.1 % | low | not evaluable | high | non important | - |
| Pruritic rash TRAE (grade 3-4) | 0.78 [0.08, 7.57] | | < 1 | | 0% | 3 studies (3/-) | 58.3 % | low | not evaluable | high | non important | - |
| Pruritus TRAE (grade 3-4) | 2.48 [0.55, 11.24] | | < 1 | | 0% | 3 studies (3/-) | 12.0 % | low | not evaluable | high | non important | - |
| Pyrexia TRAE (grade 3-4) | 1.63 [0.31, 8.42] | | < 1 | | 0% | 3 studies (3/-) | 28.2 % | low | not evaluable | high | non important | - |
| Rash TRAE (grade 3-4) | 1.21 [0.23, 6.46] | | < 1 | | 54% | 3 studies (3/-) | 41.1 % | low | not evaluable | high | non important | - |
| Renal and urinary disorders TRAE (grade 3-4) | 0.98 [0.03, 29.71] | | < 1 | | 0% | 1 study (1/-) | 50.5 % | NA | not evaluable | | non important | - |
| Respiratory, thoracic and mediastinal disorders TRAE (grade 3-4) | 1.48 [0.15, 14.67] | | < 1 | | 0% | 1 study (1/-) | 36.9 % | NA | not evaluable | | non important | - |
| Skin and subcutaneous tissue disorders TRAE (grade 3-4) | 9.64 [0.55, 170.02] | | < 1 | | 0% | 1 study (1/-) | 6.3 % | NA | not evaluable | | non important | - |
| Thyroiditis TRAE (grade 3-4) | 1.48 [0.11, 19.28] | | < 1 | | 0% | 2 studies (2/-) | 38.4 % | low | not evaluable | high | non important | - |
| Vitiligo TRAE (grade 3-4) | 1.06 [0.12, 9.11] | | < 1 | | 0% | 3 studies (3/-) | 47.9 % | low | not evaluable | high | non important | - |
| Vomiting TRAE (grade 3-4) | 2.71 [0.60, 12.20] | | < 1 | | 0% | 3 studies (3/-) | 9.7 % | low | not evaluable | high | non important | - |
| Weight decreased TRAE (grade 3-4) | 0.50 [0.04, 5.48] | | < 1 | | 0% | 2 studies (2/-) | 71.5 % | low | not evaluable | high | non important | - |
